Slu-pp-332

SLU-PP-332: The Novel, Brain-Permeable LXRβ-Selective Agonist for Neurodegeneration Research 🧠🔬

Target CNS Lipid Metabolism with Unprecedented Precision. SLU-PP-332 is not a conventional peptide; it is a first-in-class, synthetic, brain-penetrant agonist exhibiting high selectivity for the Liver X Receptor beta (LXRβ) subtype over LXRα. This pharmacological profile makes it a groundbreaking research tool specifically designed to explore the role of LXRβ in the central nervous system—particularly in clearing toxic protein aggregates, modulating neuroinflammation, and enhancing neuronal resilience—with potential relevance to Alzheimer's, Parkinson's, and other proteinopathies.

Imagine Selectively Activating the Brain's "Waste Management" and "Anti-Inflammatory" Receptor. Unlike non-selective LXR agonists that disrupt peripheral lipid metabolism, SLU-PP-332's CNS-focused action allows you to isolate LXRβ's critical functions in the brain:

• Promotion of Apolipoprotein E (ApoE) Expression: Driving the primary lipid carrier involved in amyloid-beta clearance.

• Enhancement of Phagocytosis: Potentially boosting microglial uptake of pathological protein aggregates.

• Regulation of Neuroinflammation: Modulating glial cell responses to mitigate chronic inflammatory damage.

• Support of Neuronal Energy & Survival: Influencing cholesterol transport and glucose metabolism in neurons.

This makes it a pivotal compound for deciphering LXRβ-specific pathways in neurodegenerative models and validating it as a therapeutic target.

Pioneering Neuropharmacology Demands Pioneering Quality. Researching a novel, selective CNS agent requires material of the highest synthetic and analytical standard.

• Verified Structure & High Purity: ≥98% purity, with chemical structure confirmed by NMR, HPLC, and Mass Spectrometry. ✅

• Complete Research Dossier: Full batch-specific analytical data (CoA, MS, NMR) supporting its identity, selectivity profile, and stability for in-vivo studies. 📄

• Optimized for CNS Research: Formulated to support studies requiring brain exposure and chronic dosing in rodent models of neurodegeneration. ⚙️